Expert insights on laboratory developed tests, the consequences of ending abortion protection, health equity, and more draw 18,000 attendees to ADLM 2024

CHICAGO, Aug. 1, 2024 ~ The Association for Diagnostics & Laboratory Medicine (ADLM) welcomed a record-breaking number of laboratory experts to their annual meeting, ADLM 2024, from July 28 to August 1. Formerly known as the AACC Annual Scientific Meeting & Clinical Lab Expo, this year's event showcased groundbreaking advancements in diagnostic research and technology, highlighting the crucial role that laboratory medicine plays in patient care.

According to ADLM, as of Thursday, August 1, over 18,000 laboratory medicine professionals had registered for the meeting. This marks a significant increase of 6% in attendance since the last time the ADLM Annual Meeting was held in Chicago in 2022. With one more day left in the meeting, even more attendees are expected to join.

One of the highlights of the event was a special session featuring representatives from ADLM, the American Medical Association, and the Children's Hospital Association. They discussed how the FDA's final rule placing laboratory developed tests under FDA oversight will have a negative impact on patient care. The session also included a caregiver and patient advocate who shared their perspective on why these tests are essential for timely diagnoses and treatment.

More on EntSun News

• Phinge Announces Proposal to Combat Billions in Government Waste, Fraud, and Abuse with Proactive, Hardware-Verified Netverse App-Less Platform
• New Research Links UFO Sightings to Collective Brain States During Social Stress
• Taboo: The Lost Codes of Men — A Bold New Book Confronting the Crisis of Modern Manhood
• Local Legacy Honored: Musclegram Founder Lee Millard Recognized at Vegas Classic
• Phinge's Netverse to Redefine Clinical Trial Safety and Data Integrity with Netverse Patented, Hardware-Verified Platform

Attendees were also treated to five plenary talks led by pioneers in life sciences. In the opening plenary, Dr. Patrick Bossuyt received the prestigious Wallace H. Coulter Lectureship award and spoke about his experiences leading efforts to improve diagnostic tests. He made a compelling case for why strong clinical trials of laboratory tests are necessary.

On Monday, Dr. Kojo S.J. Elenitoba-Johnson from Memorial Sloan Kettering Cancer Center discussed how proteomic data can help healthcare professionals better understand lymphomas and develop precision oncology therapies.

Tuesday's plenary speaker was Dr. Ron H.N. van Schaik from Erasmus MC - University Medical Center Rotterdam who talked about implementing pharmacogenetics as a diagnostic tool in routine healthcare. He shared both the successes and challenges of this approach.

On Wednesday, Dr. Sharon Hillier from the University of Pittsburgh explored the development of new products for HIV prevention, including those that can be used on demand and minimize exposure to antiretroviral drugs.

The closing keynote speaker, Dr. Diana Greene Foster from the University of California, San Francisco, discussed the mental health, physical health, and socioeconomic consequences faced by individuals who are unable to get an abortion.

More on EntSun News

• 'Wild Hermit Wellness' Has Achieved Bestseller Status in Just 2 Months Since Launch Of Organic Skincare Line
• Easton & Easton, LLP Sues The Dwelling Place Anaheim and Vineyard USA for Failing to Protect Minor from Church Leaders' Sexual Abuse
• Hypnotic Hijinks of HypnoMarc Rolls into Sunnyvale for One Night Only
• Lokal Media House Earns ServiceTitan Certified Marketer Status
• Wall Street's New Obsession? Tradewinds Aims to Revolutionize the $8B Gentlemen's Club Industry with National Peppermint Hippo™ Strategy $TRWD

As part of ADLM's Disruptive Technology Award competition, biotech innovators presented novel technologies that could improve accurate diagnoses for more patients. The winner was Mercy BioAnalytics with their liquid biopsy platform that detects ovarian cancer in its earliest stages by measuring tumor-derived extracellular vesicles.

The ADLM 2024 Clinical Lab Expo featured nearly 900 exhibitors and covered an impressive 271,003 net square feet. This marks a 5% increase in exhibit space since the last time the meeting was held in Chicago. The expo showcased cutting-edge tests from all laboratory medicine disciplines, including artificial intelligence, molecular diagnostics, automation, point-of-care testing, mass spectrometry, mobile health, and more.

ADLM CEO Mark J. Golden expressed his excitement about the increased attendance at ADLM 2024 after the challenges faced during the COVID-19 pandemic. He also acknowledged that this has been a challenging year for laboratory medicine professionals with the FDA's final rule on laboratory developed tests. The meeting provided a crucial opportunity for attendees to learn more about what this rule means for their labs and patient care. Golden hopes that attendees will return home inspired and eager to implement what they've learned at this year's meeting in their work. He also looks forward to seeing what next year's meeting in Chicago from July 27-31 will bring.

In conclusion, ADLM 2024 was a resounding success with record-breaking attendance and groundbreaking advancements in diagnostic research and technology. The meeting provided a vital platform for laboratory medicine professionals to learn, network, and stay updated on the latest developments in their field.

---

Show All News | Report Violation